Dogwood Therapeutics (DWTX) Stock Price, News & Analysis

Company Overview

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients. Its preclinical pipeline includes antibody and protein candidates targeting key inflammatory and fibrotic pathways. In addition to cardiovascular indications, the company is evaluating opportunities in liver and renal fibrosis, with plans to advance multiple programs into IND‐enabling studies over the coming year.

Founded in 2021 and headquartered in Vancouver, British Columbia, Dogwood Therapeutics also maintains research operations in Boston, Massachusetts. The company works in collaboration with academic institutions and clinical research organizations across North America to support its development efforts. Led by an experienced management team with backgrounds in biologics discovery and cardiovascular drug development, Dogwood is positioning itself to address significant unmet needs in fibrotic disease.

Key Stats

• Today's Range: $1.42 to $1.51
• 50-Day Range: $1.34 to $2.13
• 52-Week Range: $1.28 to $9.50
• Volume: 40,492 shs
• Average Volume: 57,317 shs
• Market Capitalization: $48.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Hold

Dogwood Therapeutics Stock Analysis - MarketRank™

Dogwood Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 276th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Dogwood Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Dogwood Therapeutics has a consensus price target of $12.00, representing about 727.6% upside from its current price of $1.45.

Amount of Analyst Coverage

Dogwood Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Dogwood Therapeutics are expected to grow in the coming year, from ($0.55) to ($0.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dogwood Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dogwood Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dogwood Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.19% of the float of Dogwood Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dogwood Therapeutics has a short interest ratio ("days to cover") of 1.46, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dogwood Therapeutics has recently decreased by 39.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dogwood Therapeutics does not currently pay a dividend.

Dividend Growth

Dogwood Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.43

News Sentiment

Dogwood Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Dogwood Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dogwood Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.30% of the stock of Dogwood Therapeutics is held by insiders.

Percentage Held by Institutions

9.05% of the stock of Dogwood Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/10/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DWTX
• CIK: 1818844
• Web: www.dwtx.com
• Phone: (866) 620-8655
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dogwood Therapeutics: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +727.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($10.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -108.57%
• Return on Assets: -30.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.86
• Quick Ratio: 5.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.33 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 33,630,000
• Free Float: 33,529,000
• Market Cap: $48.76 million
• Optionable: N/A
• Beta: 1.70